Stealth Biotherapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.11.22	Stealth BioTherapeutics Corp Announces Completion of Merger (PR Newswire)
01.11.22	Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (PR Newswire)
07.10.22	Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders (PR Newswire)
30.09.22	Stealth BioTherapeutics Announces Departure of Chief Financial Officer (PR Newswire)
15.09.22	Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events (PR Newswire)
01.08.22	Stealth BioTherapeutics To Be Taken Private In All-cash Deal (RTTNews)
01.08.22	Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction (PR Newswire)
11.07.22	STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ (PR Newswire)
27.06.22	Stealth BioTherapeutics Board Receives Preliminary Proposal Letter (RTTNews)
27.06.22	Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal (PR Newswire)
14.06.22	Stealth Granted Pre-NDA Meeting For Elamipretide To Treat Barth Syndrome (RTTNews)
14.06.22	Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome (PR Newswire)
08.06.22	Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium (PR Newswire)
31.05.22	Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome (PR Newswire)
23.05.22	Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 (PR Newswire)
12.05.22	Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy (PR Newswire)
02.05.22	STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY (PR Newswire)
11.04.22	Stealth BioTherapeutics Announces $8.5 Million in Equity Financings (PR Newswire)
30.03.22	Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation (PR Newswire)
28.03.22	Stealth Bio's Elamipretide Gets Orphan Drug Designation From FDA For Friedreich's Ataxia (RTTNews)
28.03.22	Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia (PR Newswire)
24.03.22	Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) (PR Newswire)
17.03.22	Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration (PR Newswire)
16.03.22	Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference (PR Newswire)
09.03.22	Stealth BioTherapeutics to Present at Upcoming March Investor Conferences (PR Newswire)
22.02.22	Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit (PR Newswire)
15.02.22	Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial (PR Newswire)
11.02.22	Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement (PR Newswire)
08.02.22	Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference (PR Newswire)
07.01.22	Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements (PR Newswire)
04.01.22	Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference (PR Newswire)
20.12.21	Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy (PR Newswire)
13.12.21	Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs (PR Newswire)
11.11.21	Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights (PR Newswire)
04.11.21	Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11 (PR Newswire)
20.10.21	Stealth BioTherapeutics Receives Refusal to File Letter from the FDA (PR Newswire)
07.10.21	Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting (PR Newswire)
04.10.21	Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance (PR Newswire)
23.09.21	Stealth BioTherapeutics: Preclinical Data Shows Neuroprotective Effect Of SBT-272 (RTTNews)
23.09.21	Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021 (PR Newswire)
16.09.21	Pre-market Movers: LPTX, IRNT, AGIL, IO, INDP… (RTTNews)
15.09.21	Pre-market Movers: NXTD, KAVL, SONM, MITC, BTCS… (RTTNews)
14.09.21	Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences (PR Newswire)
07.09.21	Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences (PR Newswire)
24.08.21	Stealth BioTherapeutics Submits Elamipretide NDA To FDA For Treatment Of Barth Syndrome (RTTNews)
24.08.21	Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome (PR Newswire)
11.08.21	Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference (PR Newswire)
05.08.21	Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights (PR Newswire)
30.07.21	Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5 (PR Newswire)
07.07.21	Stealth BioTherapeutics Joins the Rare Disease Company Coalition (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Stealth Biotherapeutics Corp (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten